Resource Summary Report

Generated by RRID on Aug 30, 2026

SiMa

RRID:CVCL_1695
Type: Cell Line

Proper Citation

RRID:CVCL_1695

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1695

Proper Citation: RRID:CVCL_1695

Description: Cell line SiMa is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Adrenal gland neuroblastoma

Defining Citation: PMID:10686945, PMID:11668190, PMID:20164919, PMID:22460905, PMID:23185348, PMID:25877200, PMID:26589293, PMID:27397505, PMID:30629668, PMID:30894373, PMID:31068700, PMID:35839778

Comments: Biotechnology: Used in a bioassay to measure botulinum toxin serotype A (BoNT/B) activity. Together with the monoclonal antibody produced by hybridoma 2E2A6 (Cellosaurus=CVCL_RA98)., Population: Caucasian., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: SiMa

Synonyms: SIMA

Cross References: CLO:CLO_0009018, CLDB:cl4300, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, BioGRID_ORCS_Cell_line:469, BioSample:SAMN03470930, BioSample:SAMN10988579, cancercelllines:CVCL_1695, Cell_Model_Passport:SIDM00395, ChEMBL-Cells:CHEMBL3308828, ChEMBL-Targets:CHEMBL2366067, Cosmic:753620, Cosmic:2485949, Cosmic-CLP:753620,

DepMap:ACH-000099, DSMZ:ACC-164, DSMZCellDive:ACC-164, EGA:EGAS00001000978, GDSC:753620, GEO:GSM563363, GEO:GSM887572, GEO:GSM888655, GEO:GSM1366410, GEO:GSM1670423, IARC_TP53:27575, LiGeA:CCLE_027, LINCS_LDP:LCL-1979, PharmacoDB:SIMA_1378_2019, PRIDE:PXD030304, Progenetix:CVCL_1695, PubChem_Cell_line:CVCL_1695, Wikidata:Q54953497

ID: CVCL_1695

Record Creation Time: 20220427T221542+0000

Record Last Update: 20260829T235932+0000

Ratings and Alerts

No rating or validation information has been found for SiMa.

No alerts have been found for SiMa.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 8 mentions in open access literature.

Listed below are recent publications. The full list is available at RRID .

Xie Y, et al. (2026) QW-5-70 targets the colchicine site and demonstrates antitumor activity in P-gp-overexpressing cancer models. Molecular cancer therapeutics, OF1.

Montuori G, et al. (2025) Extrachromosomal DNA-Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in MYCN-Amplified Cancers. Cancer discovery, 15(10), 2054.

Abu-Zaid A, et al. (2024) Histone lysine demethylase 4 family proteins maintain the transcriptional program and adrenergic cellular state of MYCN-amplified neuroblastoma. Cell reports. Medicine, 5(3), 101468.

Jablonowski CM, et al. (2024) Metabolic reprogramming of cancer cells by JMJD6-mediated pre-mRNA splicing associated with therapeutic response to splicing inhibitor. eLife, 12.

R??sch L, et al. (2023) ERBB and P-glycoprotein inhibitors break resistance in relapsed neuroblastoma models through P-glycoprotein. Molecular oncology, 17(1), 37.

Hou R, et al. (2022) Targeting EP2 receptor with multifaceted mechanisms for high-risk neuroblastoma. Cell reports, 39(12), 111000.

Cai J, et al. (2022) High-risk neuroblastoma with NF1 loss of function is targetable using SHP2 inhibition. Cell reports, 40(4), 111095.

Malone CF, et al. (2021) Selective Modulation of a Pan-Essential Protein as a Therapeutic Strategy in Cancer. Cancer discovery, 11(9), 2282.